Interstitial Lung Disease

Long-term survival benefit found in inhaled treprostinil treatment for pulmonary hypertension associated with IILD

A post-hoc analysis of the INCREASE trial and its open-label extension (OLE) suggests a significant long-term survival benefit associated with inhaled treprostinil treatment in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD), according to a study. The study aimed to evaluate the extended impact of inhaled treprostinil on...